LAVAL, QC, Feb. 19 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that Julia R. Brown has been appointed to the Company's Board of Directors and will become a member of the Human Resources and Corporate Governance Committee.
"With an extensive and diverse background in the life-sciences industry, including biotechnology, pharmaceuticals and drug delivery, as well as specific experience in pharmaceutical sales and marketing, Ms. Brown is a strong addition to our Board," said James R. Howard Tripp, President and Chief Executive Officer, Labopharm Inc. "We look forward to her guidance and counsel as we continue to pursue the global commercialization of our once-daily formulation of tramadol and build our product pipeline."
Ms. Brown serves as member of the Board of Directors of Tanox, Inc., Mediquest Therapeutics, Inc., and Rx3 Pharmaceuticals, Inc. She serves as a member of the commercial advisory board of CovX.. She also serves on the boards of the UCSD Foundation, the La Jolla Institute for Molecular Medicine, the Veteran's Medical Research Foundation, and CONNECT. She is a member of Tech Coast Angels, an organization that provides early stage financing and managerial assistance to technology and life-science entrepreneurs.
From 2000 to 2003, Ms. Brown was Executive Vice President of Amylin Pharmaceuticals, Inc. where she was responsible for commercial operations. She continues to serve as an Advisor to the CEO. Previously, she was Executive Vice President of Dura Pharmaceuticals. Prior to joining Dura, she was with Eli Lilly and Company for more that 25 years in progressively more senior roles. She served as Vice President of Lilly's subsidiary, IVAC Corporation and was General Manager of IVAC's Vital Signs business. She was Vice President of Marketing for Hybritech, another Lilly subsidiary.
Labopharm also announced that Mr. Robert Raich has retired from the Company's Board of Directors.
About Labopharm Inc.
Labopharm Inc. is an international specialty pharmaceutical company focused on the development of drugs incorporating the Company's proprietary advanced controlled-release technologies. The Company's lead product, a once-daily formulation of the analgesic tramadol, has been approved and launched in Europe and is currently under review for approval by the U.S. Food and Drug Administration. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process and the commercialization of the Corporation's products thereafter. Investors should consult the Corporation's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
Labopharm Inc.CONTACT: At Labopharm, Mark D'Souza, Chief Financial Officer, Tel: (450)680-0207; At The Equicom Group, Jason Hogan, Media and Investor Relations,Tel: (416) 815-0700, jhogan@equicomgroup.com; French: Eric Bouchard, Tel:(514) 844-7997, ebouchard@equicomgroup.com
